Summary
The reason for immunotherapy of malignant tumors is the demonstration of tumor antigens and the immune response to tumors. An effective defense of tumors can be prevented by different kinds of disturbances of the immune response. Therefore, methods were developed to achieve a more effective immune defense of tumors by modulation of the immune system. As examples of clinical results the data of an unspecific immunotherapy in patients with bronchial carcinoma, of a specific immunotherapy in patients with acute myelocytic leukemia, and of an adoptive immunotherapy in patients with osteogenic sarcoma are reported.
Zusammenfassung
Die rationale Begründung für eine Immuntherapie maligner Tumoren ergibt sich aus dem Nachweis von Tumorantigenen und von immunologischer Antwort auf Tumoren. Verschiedene Ursachen für Störungen der Immunantwort verhindern nicht selten eine wirksame Tumorabwehr des Organismus. Es wurde deshalb eine Reihe von Verfahren entwickelt, die über eine Modulation der Immunantwort das Tumorwachstum hemmen sollen. Als Beispiele klinischer Ergebnisse werden die Befunde einer unspezifischen Immuntherapie bei Bronchialcarcinomen, einer spezifischen Immuntherapie bei akuter myeloischer Leukämie und einer adoptiven Immuntherapie beim osteogenen Sarkom besprochen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Southam, C. M.: History and prospects of immunotherapy of cancer. Int. Conf. Immunother. Cancer. Southam, C. M., Friedman, H. (eds.). Ann. N.Y. Acad. Sci.277,1 (1976)
Klein, G.: Tumor specific transplantation antigens. Cancer Res.3, 625 (1968)
Gold, P., Freedman, S. O.: Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med.121, 439 (1965)
Hellström, L, Hellström, K. E., Sjögren, H., Warner, G.: Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int. J. Cancer7, 1 (1971)
Alexander, P., Eccles, S. A., Gauci, C. L. L.: The significance of macrophages in human and experimental tumors. In: Int. Conf. Immunobiol. Cancer. Friedman, H., Southam, C. M. (eds.). Am. N.Y. Acad. Sci.276, 124 (1976)
Kikushi, K., Ishii, Y., Ueno, H., Koshiba, H.: Cell-mediated immunity involved in autochthonous tumor rejection in rats. Ann. N. Y. Acad. Sci.276, 188 (1976)
Klein, E., Becker, S., Svedmyr, E., Jondal, M., Vanky, F.: Tumor infiltrating lymphocytes. Ann. N. Y. Acad. Sci.276, 207 (1976)
Nishioka, K., Kawamura, K., Hirayama, T., Kawashima, T., Shimada, K., Kogure, M.: The complement system in tumor immunity: Significance of elevated levels of complement in tumor bearing hosts. Ann. N. Y. Acad. Sci.276, 303 (1976)
Roitt, L: Essential immunology. Oxford, London, Edinburgh, Melborne: Blackwell 1974
Han, T.: Effect of neuraminidase on cellular immunity. In: The handbook of cancer immunology, Vol. 5. Waters, H. (ed.). New York, London: Garland STPM Press 1978
Likhite, V. V.: Review of tumor enhancement. In: The handbook of cancer immunology, Vol. 4. Waters, H. (ed.). New York, London: Garland STPM Press 1978
Hawrylko, E.: Mechanisms by which tumors escape immune destruction. In: The handbook of cancer immunology, Vol. 2. Waters, H. (ed.). New York, London: Garland STPM Press 1978
Stackpole, C. W., Jacobson, J. B.: Antigenic modulation. In: The handbook of cancer immunology, Vol. 2. Waters, H., (ed.). New York, London: Garland STPM Press 1978
Zolla-Pazner, S., Fleit, S., Kolb, J. P.: Regulation of the immune response by tumors. In: The handbook of cancer immunology, Vol. 2. Waters, H., (ed.). New York, London: Garland STPM Press 1978
Schumacher, K., Grol, M.: unveröffentlichte Befunde
Weiss, L., Glaves, D.: Immunity and metastasis. In: The handbook of cancer immunology, Vol. 1. Waters, H. (ed.). New York, London: Garland STPM Press 1978
Chirigos, M. A. (ed.): Control of neoplasia by modulation of the immune system. New York: Raven Press 1977
Shibada, H. R., Jerry, L. M., Lewis, M. G., et al.: Immunotherapy of human malignant melanoma with irradiated tumor cells oral bacillus Calmette-Guérin and levamisole. In: Int. Conf. Immunther. Cancer, Southam, C. M., Friedman, H. (eds.). Ann. N.Y. Acad. Sci.277, 355 (1976)
Gutterman, J. U., Mavligit, G. M., Schwarz, M. A., Hersh, E. M.: Immunotherapy of human solid tumours: principles of development. In: Immunological aspects of cancer. Castro, J. E. (ed.). Lancaster: MTP Press 1978
Yamamura, Y., Azuma, L, Taniyana, T., et al.: Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovis-bacillus Calmette-Guérin: Experimental and clinical results. In: Int. Conf. Immunother. Cancer. Friedman, H. (ed.). Ann. N.Y. Acad. Sci.277, 209 (1976)
Holland, J. F., Bekesi, J. G.: Comparison of chemotherapy with chemotherapy plus VCN-treated cells in acute myeolytic leukemia. In: Immunotherapy of cancer. Terry, W. D., Windhorst, D. (eds.). New York: Raven Press 1978
Rifts, R. E., Pritchard, D. J., Taylor, W. F., Gilchrist, G. S., Ivins, J. C.: Comparison of transfer-factor and combination chemotherapy as post surgical adjuvants in osteogenic sarcoma: results at three years. In: Immunotherapy of malignant diseases. Rainer, H. (ed.). Stuttgart, New York: Schattauer 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schumacher, K. 15. Stand und Ausblick bei der immunologischen Carcinomtherapie. Langenbecks Arch Chiv 349, 89–94 (1979). https://doi.org/10.1007/BF01729473
Issue Date:
DOI: https://doi.org/10.1007/BF01729473